- Agriculture
- Antibiotic/anti-viral
- Biologics
- Biomarkers
-
By Clinical Application
- Anesthesiology
- Blood & Lymphatic Disease
- CNS & Neurosciences
- Dermatology
- Diabetes, Metabolism, Endocrinology & Obesity
- Ear, Nose, & Throat
- Emergency Services
- Gastroenterology & Digestive Disease
- General & Plastic Surgery
- Health Education, Medical Training and Operations
- Heart and Vascular
- Immunology, Autoimmune & Inflammation
- Infectious Diseases
- Mental Health
- Multiple clinical applications
- Musculoskeletal Disorders, Orthopedics/Bone
- Nephrology/Renal
- Oncology
- Ophthalmology
- Orphan Diseases
- Pediatrics
- Physical Medicine & Rehabilitation
- Radiology
- Regenerative Medicine / Tissue Engineering
- Reproductive Health: Obstetrics & Gynecology
- Respiratory & Pulmonary
- Surgery
- Transplantation
- Urology
- Wound Healing
- COVID-19
- Creative Works
- Diagnostics
- Drug Delivery
- Drug screening and discovery
- Energy, Cleantech & Environmental
- Engineering & Physical Sciences
- Gene therapy
- Imaging
- Materials
- Medical Devices
- Nutraceuticals
- Other
- Research & Design Tools
- RNAi/siRNA
- Sensors & Controls
- Small molecules
- Software & Information Technology
- Stem Cells
- Vaccines
- Veterinary Medicine
Showing 12 matches for the following: Inventor: "Sullenger, Bruce" ×
Collection of novel CRISPR guide RNAs and their creation method
Unmet Need The advent of CRISPR-Cas9 technology has enabled targeted rapid modification of genes and sparked a biotechnology revolution. The CRISPR-Cas9 complex is composed of two parts: a guide RNA specific to the DNA sequence…
Aptamer anticoagulant therapy to reduce complications of ECMO treatment
Unmet Need Extracorporeal membrane oxygenation (ECMO) is a life-saving treatment for critically ill patients with low oxygen levels. During ECMO, the patient’s blood flows through an external oxygenation device. This requires co-treatment with an anticoagulant…
A universal antidote for aptamer therapeutics
Value Proposition With an ever increasing number of people taking numerous medications, the need to safely administer drugs and limit unintended side effects has never been greater. Antidote control remains the most direct means to…
Aptamers to Glycoprotein VI
Value Proposition Millions of Americans have received antiplatelet agents to prevent pathological blood clot formation (thrombosis). Platelets are the key prothrombotic element, forming aggregates that lead to blood clots. Antiplatelet therapies can counteract this process.…
Controlling coagulation with aptamer combinations and aptamer-drug combinations and their antidotes
Value Proposition Millions of Americans have received anticoagulative agents to prevent pathological blood clot formation (thrombosis). For decades, warfarin and heparin have been the centerpiece of anticoagulative treatment. In the past decade, new anticoagulative agents…
RNA Aptamers Targeting a coagulation Cascade Cofactor
Value Proposition Thrombosis (blood clots within blood vessels) is a major underlying factor in many cardiovascular diseases and a major source for complications following hospital stays and surgeries. Venous thrombosis occurs in approximately 1 per…
Ex vivo scavenging of pro-inflammatory nucleic acids by electrospun cationic nanofibers
Value proposition Chronic wounds are a challenge to treat and consume a great deal of healthcare resources around the globe. In the setting of chronic wounds, dead and dying cells are continuously releasing nucleic acids…
Inhibition of endosomal TLR-activation with nucleic acid binding polymers
Value Proposition Inflammatory and autoimmune diseases are the result of improper activation of the immune system, and can have chronic debilitating effects on quality of life. This inflammation is mediated by pattern recognition receptors (PRRs)…
RNA aptamers for thrombi imaging
Value Proposition Thrombosis (blood clots within blood vessels) is a major underlying factor in many cardiovascular diseases and a major source for complications following hospital stays and surgeries. Venous thrombosis occurs in approximately 1 per…
Induction of immunogenic cell death in cancer cells using modified ssRNAs
Value proposition Cancer immunotherapy is showing great promise against numerous cancer types in clinical trials. Consequently, this market is projected to rapidly grow to over $200 billion by 2021. Among the list of effective immunotherapies…
Development of novel therapeutic splice-switching oligonucleotides against aggressive prostate cancer
Value Proposition One in twelve men will be diagnosed with prostate cancer in their lifetime. Castration resistant prostate cancer, which resists traditional hormone therapies and continues to grow and often metastasize with poor survival outcomes,…
Aptamers to VMF
Focused aptamer libraries are constructed in accordance with a proteome (i.e., complex mixture of native biomolecules). The libraries may be screened to identify one or more candidate aptamers with desired biological activities other than specific…